Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec
An Exploratory Randomized Open-Label 2-Arm Comparison of Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec to Determine Optimum Basal Insulin Dosing Regimens in Type 1 Diabetes Mellitus Subjects
Sponsor: Diasome Pharmaceuticals
A PHASE2 clinical study on Diabetes Mellitus, Type 1, this trial is completed. The trial is conducted by Diasome Pharmaceuticals and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jul 2019 — May 2020 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Diasome Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .